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It has been reported that imatinib may have a specific pro-
tective role in blocking the fusion of the protein S of the
Coronavirus belonging to the viral surface with cell mem-
branes [1]. This role could prevent the endocytosis necessary
for the viral activation of different viral species (Sars-COV,
MERS-CoV, and IBV) [2]. No in vivo information has been
reported so far. The only information related to chronic
myeloid leukemia (CML) comes from a relatively small
series from the Hubei Province where it was found that
relatively few COVID-19+ CML patients were reported [3].
The Campus CML is an ongoing program aimed at
creating a network of physicians in Italy involved in different
aspects of the management of patients with CML, sharing
experiences and updates for the diagnosis, treatment of the
disease, identification and prevention of the specific toxicity
of the drugs used but also on possible future therapeutic
approaches. Considering the current COVID-19 emergency
in Italy, we asked Italian clinicians about the incidence of
infections among their CML patients and about the man-
agement of the disease in this unique pandemic period. On
April 6 we sent an ad hoc questionnaire to 51 Campus
CML centers throughout the country and 47 centers (92%)
have completed the online survey. Nineteen centers were
from the most affected regions: Lombardia, Piemonte,
Veneto, Emilia-Romagna. Twelve centers (42.5%) reported a
decrease in the incidence of new CML cases in this period.
Data from a large cohort of 6883 CML patients were gath-
ered: only 12 cases of confirmed COVID-19 infection were
reported (0.17%) up to the middle of April. Two of the 12
cases were healthcare professionals and 8 have been infected
in the most affected Italian regions. Only two deaths have
been recorded, one in a patient aged 91 years. Other five
patients were suspected based on the symptoms presented,
but tested negative. The majority of participants (89%)
declared that CML patients were tested only in case of fever
and/or related symptoms and/or who had been in close
contact with a positive subject, but not routinely. In Italy,
testing is routinely performed on inpatients. Eight centers
(17%) reported difficulties in performing a baseline diag-
nostic work-up and molecular monitoring to detect MRD
during treatment. Sixty-six percent of centers postponed the
molecular analysis by 1–2 months during this emergency if
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patients were at least in MR3 or if they were in deep and
stable molecular response. Patients who did not have to
perform a molecular monitoring were checked prevalently by
telephone or by email during the COVID-19 pandemic. The
COVID-19 emergency had a repercussion on the treatment-
free remission (TFR) strategy: 58% of participating physi-
cians did not propose a possible discontinuation and 24% of
patients already in TFR have had to modify the molecular
monthly monitoring approach. We recorded changes also in
the delivery of drugs: while imatinib delivery was not
affected due to local pharmacy distributions, 36% of physi-
cians reported consequences for second-generation TKIs
subject to AIFA (the Italian Medicine Agency) monitoring in
Italy. In some instances, delivery was carried out directly at
the patient’s home (12%) or a supply for more months has
been granted (10%) by the treating center.
The activity of ongoing CML trials has already been
affected by the emergency: 34% of physicians have stopped
enrollment and 8% have continued with the ongoing trials
with some difficulties in the planned follow-up of enrolled
patients. AIFA issued a decree that allowed patients enrolled in
a trial and not able to reach the center to perform the requested
tests at a hospital near home with a complete reimbursement:
51% of interviewed centers adopted this strategy.
These results of our survey show that the incidence of
COVID-19 infection has so far proven extremely low in CML
patients treated with TKIs. These data are in line with what
observed in adult patients with Ph+ acute lymphoblastic
leukemia (Ph+ ALL) in Italy, where patients are induced with
a TKI plus steroids and no systemic chemotherapy, and could
continue to be managed even at the peak of the COVID-19
outbreak [4]. Taken together, the data gathered on over 7000
cases of CML and Ph+ ALL support a potential role of TKIs
in protecting patients from COVID-19 infection. To con-
clusively answer this question a randomized study (EudraCT
2020-001236-10) is verifying the effect of imatinib in pre-
venting pulmonary vascular leak in patients with severe
COVID-19 disease. Although the likelihood of developing a
symptomatic COVID-19 infection in CML patients in Italy is
close to zero and lower than that of the general population in
Italy, the current pandemic emergency is, however, already
negatively impacting on different aspects of the day-to-day
management of patients, on disease monitoring and on
treatment decisions, as well as on the enrollment in and
compliance to clinical trials.
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